AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme

This article was originally published here

The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for dyslipidaemia and familial hypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is

The post AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply